晶泰科技海外收购LCC，强化“AI+机器人”药物研发实力

Core Viewpoint - XtalPi Holdings Limited has completed the acquisition of Liverpool ChiroChem, enhancing its capabilities in AI-driven autonomous experimental platforms for chemical exploration, which will better serve clients in drug development, new materials discovery, and high-value chemicals [2][4]. Group 1: Acquisition Details - The acquisition of Liverpool ChiroChem (LCC) will strengthen XtalPi's "AI + Robotics" platform in the chemical exploration domain [2]. - LCC's founder, Dr. Paul Colbon, expressed excitement about leveraging AI and robotics to explore a broader chemical space and expedite the discovery of high-value molecules [4]. - LCC, established in 2014, focuses on the design and synthesis of novel chiral molecules and has developed the PACE technology platform, which integrates AI software with automation for efficient molecular screening and synthesis [4][5]. Group 2: Technological Synergy - LCC possesses a leading global database of chiral chemical entities, providing high-quality data support for AI models in chiral molecular exploration [5]. - The collaboration between XtalPi and LCC will enhance capabilities in high-throughput and micro-scale molecular library construction, complementing XtalPi's large-scale molecular library technology [5]. - XtalPi continues to enhance its technical strength in chemical exploration through strategic partnerships, incubation, joint research, and acquisitions [5]. Group 3: Company Background - XtalPi was founded in 2015 by three physicists from MIT and operates as an innovative R&D platform powered by quantum physics, AI, and robotics [6]. - The company provides drug and materials science R&D solutions for global and domestic companies across various industries, including pharmaceuticals, agricultural technology, energy, and new chemicals [6].